The estimated Net Worth of Ian T Clark is at least $2.4 Milione dollars as of 12 June 2024. Mr. Clark owns over 6,776 units of Agios Pharmaceuticals Inc stock worth over $694,648 and over the last 8 years he sold AGIO stock worth over $1,372,670. In addition, he makes $332,467 as Independent Director at Agios Pharmaceuticals Inc.
Ian has made over 44 trades of the Agios Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 6,776 units of AGIO stock worth $300,245 on 12 June 2024.
The largest trade he's ever made was exercising 81,772 units of Agios Pharmaceuticals Inc stock on 15 April 2019 worth over $341,807. On average, Ian trades about 2,246 units every 23 days since 2016. As of 12 June 2024 he still owns at least 15,677 units of Agios Pharmaceuticals Inc stock.
You can see the complete history of Mr. Clark stock trades at the bottom of the page.
Ian T. Clark is Independent Director of the Company. Mr. Clark has served as a member of our board of directors since December 2016. Mr. Clark has more than 30 years of experience in the biotechnology industry. Mr. Clark currently serves as an operating partner at Blackstone Life Sciences, a private investment firm. Prior to that, he was chief executive officer and head of North American Commercial Operations of Genentech (now a member of the Roche Group), a position he held from 2010 to 2016. Mr. Clark also led the Genentech executive committee and was a member of the Genentech board of directors. Mr. Clark joined Genentech in 2003 as senior vice president and general manager, bio-oncology. In 2005, he was named senior vice president, commercial operations and became a member of the executive committee, and in 2006, he was named executive vice president, commercial operations. In 2009, he was named head of global product strategy and chief marketing officer of Roche. Prior to joining Genentech, Mr. Clark held roles of increasing responsibility at Novartis, Sanofi-Synthelabo SA (Aventis SA), Ivax Pharmaceuticals, Inc. and G.D. Searle, LLC, a subsidiary of Monsanto Corporation in the United States, Canada, the United Kingdom, France and Eastern Europe. Mr. Clark is a member of the boards of directors of publicly-traded biopharmaceutical companies Takeda Pharmaceutical Company Limited, Guardant Health, Inc., Forty Seven, Inc. and Corvus Pharmaceuticals, Inc., and is on the board of AvroBio, Inc., a private biotechnology company. He was formerly on the boards of directors of Shire plc (prior to its acquisition by Takeda), Kite Pharma, Inc. (prior to its acquisition by Gilead), Dendreon Corporation, Vernalis plc, and TerraVia Holdings, Inc.
As the Independent Director of Agios Pharmaceuticals Inc, the total compensation of Ian Clark at Agios Pharmaceuticals Inc is $332,467. There are 14 executives at Agios Pharmaceuticals Inc getting paid more, with Jacqualyn Fouse having the highest compensation of $16,608,000.
Ian Clark is 59, he's been the Independent Director of Agios Pharmaceuticals Inc since 2016. There are 11 older and 11 younger executives at Agios Pharmaceuticals Inc. The oldest executive at Agios Pharmaceuticals Inc is Dr. Tak Wah Mak, 75, who is the Co-Founder & Member of Scientific Advisory Board.
Ian's mailing address filed with the SEC is C/O GOODRX HOLDINGS, INC., 2701 OLYMPIC BOULEVARD, SANTA MONICA, CA, 90404.
Over the last 11 years, insiders at Agios Pharmaceuticals Inc have traded over $77,887,085 worth of Agios Pharmaceuticals Inc stock and bought 3,229,562 units worth $154,554,190 . The most active insiders traders include Kevin P Starr, Robert Nelsen e John Maraganore. On average, Agios Pharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $765,588. The most recent stock trade was executed by Rahul D. Ballal on 11 August 2024, trading 2,302 units of AGIO stock currently worth $102,002.
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Agios Pharmaceuticals Inc executives and other stock owners filed with the SEC include: